Cadralazine

CAS: 64241-34-5

Ref. 3D-FC171982

Información del producto

• Nombre: Cadralazine
• Sinónimos: 2-(6-(Ethyl(2-hydroxypropyl)amino)-3-pyridazinyl)-hydrazinecarboxylic acid ethyl ester, 3-(2-Carbethoxyhydrazino)-6-(N-(2-hydroxypropyl)ethylamino)pyridazine, 3-(6-(Ethyl-(2-hydroxypropyl)amino)pyridazin-3-yl)carbazic acid ethyl ester, Brn 0894631, Cadral, Cadralazina, Cadralazina [INN-Spanish], Cadralazina [Spanish], Cadralazine [INN:BAN:JAN], Cadralazinum, Cadralazinum [INN-Latin], Cadraten, Cadrilan, Carbazic acid, 3-(6-(ethyl(2-hydroxypropyl)amino)pyridazin-3-yl)-, ethyl ester, Cgp 18684E, Dc-826, Ethyl 2-(6-(ethyl(2-hydroxypropyl)amino)-3-pyridazinyl)hydrazinecarboxylate, Ethyl 2-{6-[Ethyl(2-Hydroxypropyl)Amino]Pyridazin-3-Yl}Hydrazinecarboxylate, Ethyl 6-(ethyl(2-hydroxypropyl)amino)-3-pyridazinecarbazate, Hydrazinecarboxylic acid, 2-(6-(ethyl(2-hydroxypropyl)amino)-3-pyridazinyl)-, ethyl ester, Isf 2469, Presmode, Unii-8T96I3U713

Descripción

Cadralazine is a drug that belongs to the group of pharmacological agents. It is used for the treatment of chronic renal failure, pulmonary hypertension, and heart failure. Cadralazine has been shown to have long-term efficacy in the treatment of chronic renal failure and pulmonary hypertension. Cadralazine also inhibits cellular calcium accumulation by interfering with the conversion of citrate to pergolide mesylate or isepamicin sulfate. This inhibition may be responsible for its therapeutic effects on infectious diseases, metabolic disorders, and cardiac problems in geriatric patients. Cadralazine has pharmacokinetic properties that allow it to cross the blood-brain barrier more easily than other drugs in its class. This makes it a potential treatment for neurological disorders such as Parkinson's disease and Alzheimer's disease.

• Marca: Biosynth

Propiedades químicas

• Peso molecular: 283.33 g/mol
• Fórmula: C₁₂H₂₁N₅O₃
• Pureza: Min. 95%